首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment
【24h】

Poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment

机译:聚(乙烯醇)-接枝-聚(丙交酯-共-乙交酯)纳米颗粒用于局部转运紫杉醇用于再狭窄治疗

获取原文
获取原文并翻译 | 示例
       

摘要

Catheter-based local delivery of biodegradable nanoparticles (NP) with sustained release characteristics represents a therapeutic approach to reduce restenosis. Paclitaxel-loaded NP consisting of poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) (PVA-g-PLGA) with varying PLGA chain length as well as poly(lactide-co-glycolide) (PLGA), were prepared by a solvent evaporation technique. NP of < 180 nm in diameter characterized by photon correlation spectroscopy (PCs), scanning electron microscopy (SEM), and atomic force microscopy (AFM) are spherical and show smooth surfaces. Yields typically range from 80 to 95% with encapsulation efficiencies between 77 and 87%. The extent of initial in vitro paclitaxel release was affected by the PVA-g-PLGA composition. Blank nanoparticles from PVA(300)-g-PLGA(30) and PVA(300)-g-PLGA(15) showed excellent biocompatibility in rabbit vascular smooth muscle cells (RbVSMC) at polymer concentrations of 0.37 mg/ml. Paclitaxel-loaded NP have an increased antiproliferative effect on cells in comparison to free drug. Confocal laser scanning microscopy of RbVSMC confirmed cellular uptake of nanoparticles composed of fluorescently labeled PVA(300)-g-PLGA(15) loaded with Oregon Green labeled paclitaxel. Cells showed a clearly increased fluorescence activity with a co-localization of paclitaxel and polymer nanoparticles during incubation with particle suspension. To evaluate the antirestenotic effect in vivo, paclitaxel-loaded nanoparticles were administered locally to the wall of balloon-injured rabbit iliac arteries using a porous balloon catheter. As a result a 50% reduction in neointimal area in vessel segments treated with paclitaxel loaded nanoparticles compared to control vessel segments could be observed (local paclitaxel nanoparticle treated segments 0.80 +/- 0.19 mm(2), control segments 1.58 +/- 0.6 mm(2); p < 0.05). (c) 2007 Elsevier B.V. All rights reserved.
机译:具有持续释放特性的基于导管的可生物降解纳米颗粒(NP)的局部递送代表减少再狭窄的治疗方法。载有紫杉醇的NP是由具有不同PLGA链长的聚乙烯醇-接枝-聚丙交酯-乙交酯共聚物(PVA-g-PLGA)和聚丙交酯-乙交酯共聚物(PLGA)组成的通过溶剂蒸发技术制备。用光子相关光谱法(PCs),扫描电子显微镜(SEM)和原子力显微镜(AFM)表征的直径<180 nm的NP是球形的,并显示光滑的表面。产率通常为80%至95%,封装效率为77%至87%。体外紫杉醇的初始释放程度受PVA-g-PLGA组成的影响。来自PVA(300)-g-PLGA(30)和PVA(300)-g-PLGA(15)的空白纳米颗粒在聚合物浓度为0.37 mg / ml的兔血管平滑肌细胞(RbVSMC)中显示出优异的生物相容性。与游离药物相比,载有紫杉醇的NP对细胞具有增强的抗增殖作用。 RbVSMC的共聚焦激光扫描显微镜检查证实了纳米颗粒的细胞摄取,该纳米颗粒由荧光标记的PVA(300)-g-PLGA(15)组成,并带有俄勒冈绿色标记的紫杉醇。在与颗粒悬浮液孵育期间,细胞显示紫杉醇和聚合物纳米颗粒共定位,荧光活性明显增强。为了评估体内抗再狭窄作用,使用多孔球囊导管将紫杉醇负载的纳米颗粒局部给药至球囊损伤的兔动脉壁。结果可以观察到,与对照血管段相比,用紫杉醇纳米颗粒处理的血管段新内膜面积减少了50%(局部紫杉醇纳米粒子处理的段0.80 +/- 0.19 mm(2),对照段1.58 +/- 0.6 mm (2); p <0.05)。 (c)2007 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号